Previous close | 4,021.00 |
Open | 4,067.33 |
Bid | 4,067.33 x 100 |
Ask | 0.00 x 100 |
Day's range | 4,067.33 - 4,067.33 |
52-week range | 3,880.00 - 7,356.00 |
Volume | |
Avg. volume | 55 |
Market cap | 607.984B |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | 19.40 |
EPS (TTM) | 209.61 |
Earnings date | 20 Apr 2022 - 25 Apr 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.